肝癌细胞67kD层粘连蛋白受体N-糖链结构与功能的变化

探讨肝癌细胞与正常肝细胞 6 7kD层粘连蛋白受体 (6 7LR)N 糖链结构与功能的差异 .采用流式细胞术检测SMMC 772 1肝癌细胞和L 0 2正常肝细胞膜表面 6 7LR的表达 ,并分别从这 2株细胞分离纯化到高亲和力的 6 7LR ,利用凝集素结合分析其糖链结构 ,并用肽 N 糖苷酶水解N 糖链 ,观察糖链在与层粘连蛋白结合过程中的作用 .结果发现 ,L 0 2细胞膜表面 6 7LR表达的阳性率为5 5 3% ,而SMMC 772 1细胞为 34.7% ,这两株细胞 6 7LR与伴刀豆素 (ConA)的结合能力无显著差异 ,但SMMC 772 1细胞的 6 7LR与麦胚凝集素的结合能力明显高于L 0 2细胞的 6 7LR ,说明 2株细胞 6 7LR的糖链结构存在显著差异 .当N 糖链被切除后 ,SMMC 772 1细胞的 6 7LR与层粘连蛋白的结合能力明显下降 ,而L 0 2细胞则没有变化 .这些资料表明 ,SMMC 772 1肝癌细胞和L 0 2正常肝细胞与层粘连蛋白结合能力的差别 ,以及两株细胞的 6 7LR与层粘连蛋白结合能力的不同 ,很可能是由于这两株细胞的层粘连蛋白受体的N 糖链结构不同所引起     

67kD层粘连蛋白受体的克隆、表达及其对肝癌细胞侵袭能力的影响

探讨细胞膜表面 6 7kD层粘连蛋白受体 (6 7kDlamininreceptor ,6 7LR)在肝癌细胞侵袭转移中的作用 ,从肝癌细胞中提取RNA ,通过RT PCR扩增 6 7LR的前体——— 37kD层粘连蛋白受体前体(37kDlamininreceptorprecursor,37LRP)基因并定向克隆到真核表达载体pcDNA3.1 myc His(- )A ,采用脂质体将重组质粒转染到HepG2肝癌细胞中 ,通过G4 1 8筛选和RT PCR、流式细胞术鉴定 ,获得了细胞膜表面 6 7LR高表达 (阳性率为 6 9.2 % )和低表达 (阳性率为 1 1 .7% )的细胞克隆 ,采用体外细胞侵袭实验测定不同细胞的侵袭能力 ,发现膜表面 6 7LR高表达的细胞侵袭能力明显高于低表达及不表达细胞 ,说明 6 7LR在肝癌细胞侵袭转移过程中可能具有重要意义     

USP9X低表达通过下调Mcl-1促进肝癌细胞凋亡

研究抑制泛素特异性蛋白酶9X（ubiquitin-specific protease 9X,USP9X）对人肝癌（primary hepatocellular carcinoma,HCC）细胞SMMC7721和HepG2中髓细胞白血病-1（myeloid cell leukemia-1,Mcl-1）蛋白的表达调控及对细胞凋亡和生长活力的影响。实验分为USP9X-siRNA组和阴性对照NC组两组进行分析。通过Western blot技术分别检测USP9X在肝癌细胞SMMC7721、HepG2和正常人肝细胞株L02中的蛋白表达情况;应用化学合成USP9X-siRNA转染肝癌细胞SMMC7721和HepG2,通过Western blot、流式细胞仪和MTT检测转染前后Mcl-1的蛋白表达差异以及细胞凋亡和生长活力变化。结果表明,USP9X在肝癌细胞SMMC7721和HepG2中的蛋白表达水平均高于正常肝细胞L02（t=15.155,P=0.000;t=9.171,P=0.001）;SMMC7721和HepG2细胞中抑制USP9X能明显下调Mcl-1的蛋白表达,并导致细胞凋亡增加和生长活力降低。提示,肝癌细胞SMMC7721和HepG2中USP9X表达上调;USP9X表达降低可能通过下调Mcl-1的蛋白表达进而诱导人肝癌细胞SMMC7721和HepG2的凋亡。     

人67kD层粘连蛋白受体在毕赤酵母中的表达及活性分析

为实现人67kD层粘连蛋白受体(Human 67kD Laminin Receptor,67LR)蛋白的分泌表达,采用DNA重组技术将67LR cDNA片段插入分泌型酵母表达载体pPIC9K中,构建了相应的重组表达质粒pPIC9K-67LR并在GS115毕赤酵母菌株中表达,每升培养基经亲和层析可纯化目的蛋白12.56mg。纯化的目标蛋白能够与肺癌A549细胞竞争性结合其配体分子LN-1,具有相应的生物学活性,从而为深入研究人67LR的结构与功能奠定了基础。     

层粘连蛋白与膜受体结合下膜受体构象与膜脂有序性的研究

配体蛋白与细胞膜受体蛋白结合后,可引起膜受体的构象与膜脂的有序性变化.本文研究外源性层粘连蛋白与腹水肝癌细胞膜受体结合后膜热量变化,膜序参数改变和膜电荷及细胞迁移率的变更.就膜蛋白构象与膜脂有序性以及膜电荷等方面改变的生理意义与层粘连蛋白抗癌细胞脱落转移寻找理论关系.本文应用微量量热法、顺磁共振和细胞电泳等技术,得知层粘连蛋白与癌细胞膜作用后细胞膜有放热效应,膜流动性增大,细胞电泳动变慢.癌细胞膜的这些变化对于限制癌的恶性生长与脱落均起重要作用.     

层粘连蛋白受体及其在肿瘤转移中的作用

本文重点介绍近几年来国内外有关层粘连蛋白受体的研究进展:层粘连蛋白受体的分离纯化及理化性质;它在正常细胞中的功能,尤其是在癌转移中的作用。     

非洲绿猴层黏连蛋白受体的克隆、表达及纯化

目的:克隆、表达非洲绿猴层黏连蛋白受体(LR),对该受体蛋白进行纯化、复性研究。方法:采用RT-PCR从Vero-E6细胞总RNA中扩增非洲绿猴LR的cDNA序列,克隆到pGEM-TEasy载体上;将LR编码区插入到表达载体pET22b( ),转化大肠杆菌BL21(DE3);用IPTG进行诱导表达;用镍亲和柱进行亲和纯化;采用分部透析方法进行复性。结果:非洲绿猴LR基因序列与人LR的基因编码序列有16个碱基差异,但蛋白序列只有1个氨基酸的改变。LR蛋白以包涵体形式表达。采用分部透析方法可使部分蛋白得到复性。结论:克隆了首个非洲绿猴的相对分子质量为37000的LR的基因,与人LR基因序列有16个碱基差异,但其中15处都为同义突变,所以二者的蛋白质序列只有1个氨基酸改变,即293位D→E,提示LR在进化中具有很大的保守性。     

能在肝癌细胞特异表达的自主复制型肝导向基因转移系统

构建了以人甲胎蛋白基因上游调控序列控制外源基因的表达的自主复制型EB病毒复制子载体pEBAF.该载体与半乳糖基化组蛋白结合组成了一种能为肝细胞表面特异受体识别并内在化的核酸蛋白复合物,能通过肝细胞受体介导的内吞作用以非病毒感染的形式,将外源基因导入细胞内自主复制并仅在产甲胎蛋白的肝癌细胞特异表达.这种新型的基因转移系统,具有比直接使用重组病毒颗粒感染细胞更高的安全性,有应用于原发性肝癌的基因治疗的前景     

外源性层粘连蛋白对腹水型肝癌细胞内微丝组装和细胞游动的作用

本文研究外源性层粘连蛋白与癌细胞膜上受体结合调节胞内肌动蛋白微丝组装与改变细胞游动之间的关系,以及影响膜上层粘连蛋白受体的侧向扩散运动及膜脂分子流动性变化之间的关系.用各种荧光技术,如荧光显微米,荧光漂白恢复技术和荧光流式细胞术得到了明显的证据.层粘连蛋白与肝癌细胞膜有结合,使分散的腹水肝癌细胞粘连聚集,并膜下周动蛋白微丝增加,当把癌细胞分开则细胞从原位游动很大距离.如不分离粘连的细胞可减少其脱落和转移.层粘连蛋白与受体结合则受体的侧向扩散系数减小,膜脂流动性降低,使膜上分子运动受影响,对癌的生长不利.     

67ku层黏连蛋白受体促进肝癌细胞MMP-2和MMP-9的表达

目的 研究分析67ku层黏连蛋白受体（laminin receptor,67LR）与肝癌细胞基质金属蛋白酶（matrix metalloproteinases,MMPs）及其组织抑制因子（tissue inhibitor of metalloproteinases,TIMPs）表达的关系,探讨67LR促进肝癌细胞体外侵袭能力的分子机制.方法 以67LR转染HepG2的稳定细胞株及其对照细胞为材料,采用半定量RT-PCR分析目前已知的23种MMPs和4种TIMPs的表达及变化情况,对表达有变化的基因采用荧光定量PCR进行验证,采用明胶酶谱分析MMP活性的变化。结果 半定量RT-PCR和荧光定量PCR发现,67LR高表达的LR4细胞,其MMP2,9的表达比67LR低表达的LR6及对照组pcDNA-1细胞明显升高,明胶酶谱分析也揭示,LR4细胞分泌的MMP-2和MMP-9的活性明显上升。结论 67LR可以促进肝癌细胞MMP-2和MMP-9的表达和分泌,从而促进肝癌细胞体外侵袭能力。     

多天线糖链对运铁蛋白与受体结合及内吞的研究

应用系列凝集素柱层析法（伴刀豆球蛋白,小扁豆凝集素,欧曼陀罗凝集素）分别从正常人血清及孕妇血清中提纯含有二天线无核心岩藻糖复杂型糖链的运铁蛋白及含有多天线无核心岩藻糖复杂型糖链的运铁蛋白。与正常的含有二天线糖链的运铁蛋白相比,含有多天线糖链的运铁蛋白与ＳＭＭＣ－７７２１细胞膜表面的运铁蛋白受体的亲和力下降,但最大结合量不变,此外,其在内吞过程中于细胞膜上的停留时间延长。结果表明糖链结构改变对运铁蛋白的功能有影响。     

2′,4′-Dihydroxy-6′-methoxy-3′,5′-dimethylchalcone,from buds of Cleistocalyx operculatus,induces apoptosis in human hepatoma SMMC-7721 cells through a reactive oxygen species-dependent mechanism

Nowadays, much effort is being devoted to detect new substances that not only significantly induce the death of tumor cells, but also have little side effect on normal cells. Our previous study showed that 2′,4′-dihydroxy-6′-methoxy-3′,5′-dimethylchalcone (DMC) exhibited significant cytotoxic potential with an IC₅₀ value of 32.3 ± 1.13 μM against SMMC-7721 cells and could induce SMMC-7721 cells apoptosis. In the present study, we found that DMC was almost nontoxic to human normal liver L-02 and human normal fetal lung fibroblast HFL-1 cells as their IC₅₀ values (111.0 ± 4.57 and 152.0 ± 4.83 µM for L-02 and HFL-1 cells, respectively) were much higher. To further explore the apoptotic mechanism of DMC, we investigated the role of the reactive oxygen species (ROS) in the apoptosis induced by DMC in SMMC-7721 cells. Our results suggested that the cytotoxicity and the generation of intracellular ROS were inhibited by N-acetylcysteine (NAC). Reversal of apoptosis in NAC pretreated cells indicated the involvement of ROS in DMC-induced apoptosis. The loss of mitochondrial membrane potential (ΔΨm) induced by DMC was significantly blocked by NAC. NAC also prevented the decrease of Caspase-3 and -9 activities, the increase of Bcl-2 protein expression and the decrease of p53 and PUMA protein expressions. Together, these results indicated that ROS played a key role in the apoptosis induced by DMC in human hepatoma SMMC-7721 cells.     

Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression

Osteopontin (OPN) is over-expressed in a variety of cancers, but its role in hepatocellular carcinoma (HCC) progression has not been clarified. In this study, weakly tumorigenic, non-metastastic human HCC cell line SMMC-7721 cells were forced to over-express OPN via stable transfection. A series of functional assays were performed to assess the effects of OPN on tumor cell behaviors and cDNA microarray was used to identify the genes regulated by OPN. The results showed that OPN significantly enhanced the migration and invasion of SMMC-7721 cells in vitro. In addition, CD44v6 antibody could significantly inhibit the invasion of OPN over-expressing SMMC-7721 cells. Moreover, MMP-2 and uPA expressions were significantly up-regulated in OPN over-expressing SMMC-7721 cells. Together, these findings indicate that OPN enhanced HCC cells invasion through interaction with its receptor CD44v6 and increased MMP-2 and uPA expressions, providing at least one mechanism for OPN-mediated HCC progression and metastasis.     

地衣霉素对细胞膜表面运铁蛋白受体功能的影响

应用抑制糖蛋白Ｎ－糖链合成的地衣霉素处理ＳＭＭＣ－７７２１人肝癌细胞,３Ｈ甘露糖掺入实验显示细胞膜表面糖蛋白Ｎ－糖链的合成受到显著抑制,但细胞膜表面运铁蛋白受体内吞再循环的过程无显明变化,进一步的研究表明受体与运铁蛋白的亲和力亦无改变,但细胞膜表面运铁蛋白受体数减少。结果提示用地衣霉素处理细胞后,在内质网合成的无Ｎ－糖链的运铁蛋白受体影响其运输到细胞膜表面表达。     

FOXQ1在肝癌中的临床意义及其对SMMC-7721细胞体外血管形成的影响

探讨叉头框蛋白Q1(forkhead box Q1, FOXQ1)基因在肝癌中的临床意义及对肝癌细胞体外血管生成作用.利用 qRT-PCR法及Western印迹法,检测24例肝癌、癌旁组织、正常肝细胞L02及肝癌细胞SMMC-7721中FOXQ1的mRNA和蛋白质的表达;利用免疫组织化学法检测68例肝癌及癌旁组织中FOXQ1的蛋白质表达.合成shRNA-FOXQ1及shRNA-NC慢病毒,转染到SMMC-7721细胞.用体外血管生成实验检测转染shRNA-FOXQ1的肝癌细胞血管生成能力. 用qRT-PCR和Western印迹法检测细胞间FOXQ1、VEGF基因和蛋白质的表达.结果显示,癌组织和SMMC-7721细胞中FOXQ1 mRNA和蛋白质的表达均高于癌旁组织和正常肝细胞(P<0.05),FOXQ1蛋白的表达与TNM分期、肿瘤分化程度、肿瘤数目、肿瘤大小等参数差异显著(P<0.05).shRNA-FOXQ1组血管生成能力明显低于shRNA-NC组和空白组(P<0.05),FOXQ1、VEGF基因和蛋白质的表达也明显低于shRNA-NC组和空白组(P<0.05).研究结果证实,FOXQ1在肝癌中高表达,如果沉默FOXQ1的表达可抑制肝癌细胞血管生成,与肝癌的临床病理特征密切相关.     

Differential regulation of the expression of aquaporins 3 and 9 by Auphen and dbcAMP in the SMMC-7721 hepatocellular carcinoma cell line

Aquaglycero-aquaporins (agAQPs) are the structural foundation of rapid water transport and they appear to participate in cancer proliferation and malignancy. AQP3 expression is increased and AQP9 expression is decreased in hepatocellular carcinoma (HCC) compared to normal liver, which suggests their possible use as targets for cancer treatment. AQP-based modifiers, such as Auphen and dibutyryladenosine 3′, 5′-cyclic monophosphate (dbcAMP), might be used to treat several diseases and as chemical tools for assessing the functions of AQPs in biological systems. We investigated the effects of both Auphen on AQP3 and dbcAMP on AQP9 in SMMC-7721 cells. We used western blotting, real-time quantitative polymerase chain reaction (qPCR) and immunohistochemistry to evaluate changes in AQP3 and AQP9 expression in SMMC-7721 cells after culturing with Auphen and dbcAMP, respectively. We also determined the proliferation of SMMC-7721 cells. We found that compared to HL-7702 (L02) liver cells, Auphen increased AQP3 expression in tumor cells, whereas dbcAMP decreased expression of AQP9 in these cells. Also, high concentrations of Auphen and dbcAMP inhibited proliferation of SMMC-7721 cells in vitro. Auphen and dbcAMP may inhibit HCC development and could be considered targets for HCC diagnosis and therapy.     

Downregulation of NIN/RPN12 binding protein inhibit the growth of human hepatocellular carcinoma cells

The ribosome assembly factor NIN/RPN12 binding protein (Nob1) has been suggested to be essential for processing of the 20S pre-rRNA to the mature 18S rRNA, and is also reported to participate in proteasome biogenesis. However, it is unclear whether Nob1 is involved in tumor cells growth. The aim of this study was to determine whether the suppression of Nob1 by short hairpin RNA (shRNA) inhibits the growth of human hepatocellular carcinoma (HCC) cells. Recombinant lentiviral shRNA expression vector carrying Nob1 was constructed and then infected into human HCC cell line SMMC-7721. The growth properties of SMMC-7721/pGCSIL-GFP-shNC and pGCSIL-GFP-shNob1 cells were determined by MTT, BrdU incorporation assay, and flow cytometric analysis. In addition, the colony formation and tumor growth ability in nude mice were detected to define the function of Nob1 in cell transformation and tumorigenesis. Our data showed that the growth and proliferation of SMMC-7721/pGCSIL-GFP-shNob1 cells were significantly reduced compared with the SMMC-7721/pGCSIL-GFP-shNC. In addition, the colony formation was impaired after the suppression of Nob1 in SMMC-7721 cells. And in vivo, the tumor formation ability of the SMMC-7721/pGCSIL-GFP-shNob1 cells was significantly reduced compared with the control cells. Our data support that Nob1 is an important regulator of the tumorigenic properties of human HCC and could be used as a candidate therapeutic target in human HCC.     

A humanized monoclonal antibody constructed from intronless expression vectors targets human hepatocellular carcinoma cells

An anti-human hepatocellular carcinoma (HCC) monoclonal antibody, hHP-1, was genetically humanized from a murine monoclonal antibody. In this study, a concept of positional template approach was applied to design the amino acid sequence of hHP-1's variable region, and synthetic DNA fragments for protein expression were produced through overlapping PCR from single strand oligonucleotides. Synthetic DNA fragments and human antibody constant region cDNA were used to construct two CMV promotor-based expression vectors for the antibody light and heavy chains, in which the variable region was connected directly to the constant region without an intron sequence. Completely assembled humanized antibody was successfully expressed in mammalian cells as IgG1 kappa molecules and purified using protein A affinity column. The immunogenicity of the hHP1 was estimated by the amino acid sequence and determined through a HAMA (human anti-murine antibody) serum reaction assay. Results indicated that the immunogenicity of hHP-1 was significantly reduced. In vitro binding activity assay showed that the hHP-1 had retained its binding function to a human HCC SMMC-7721 cell-line, without cross binding to other human normal tissues. Immunofluorescence staining showed that hHP-1 had a strong binding activity to SMMC cells. A competitive binding assay showed that the relative binding activity of hHP-1 was approximately 25% binding activity of the original murine antibody. Our results indicate that a humanized antibody could be produced using intronless vectors and expressed as a complete IgG1 kappa antibody. Hence we believe that hHP-1 could be a potential candidate for HCC treatment.